Hydroxyurea

Introduction Overview

Generic Name

hydroxyurea

Brand Name

Droxia, Hydrea, Siklos, Mylocel, Xromi

Dosage Form

oral capsule (200 mg; 300 mg; 400 mg; 500 mg), oral tablet (100 mg; 1000 mg)

Drug Class

Antimetabolites

Pharmacokinetics

Absorption:
Hydroxyurea is rapidly absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations are usually achieved within 1 to 4 hours. Its high oral bioavailability allows for effective systemic exposure after oral dosing. The absorption is generally not affected by food intake, permitting administration with or without meals. However, handling precautions must be observed due to its cytotoxic properties.

Distribution:
Following absorption, hydroxyurea is widely distributed throughout body tissues and fluids. It readily crosses cell membranes due to its low molecular weight and moderate lipophilicity. The apparent volume of distribution ranges approximately from 0.5 to 0.8 L/kg, reflecting distribution mainly into total body water. Hydroxyurea also penetrates the cerebrospinal fluid to some extent. It is not significantly bound to plasma proteins, which facilitates its tissue dissemination. This distribution profile supports its efficacy in targeting proliferative cells in bone marrow and certain malignancies.

Metabolism:
Hydroxyurea undergoes limited hepatic metabolism. The primary metabolic pathway remains incompletely characterized but may involve enzymatic transformation to inactive metabolites, including its conversion to nitric oxide species which may contribute to its pharmacological activities. Unlike many cytotoxic agents, hydroxyurea is not extensively processed by cytochrome P450 enzymes, reducing risks for complex drug-drug interactions mediated by hepatic metabolism. The minimal hepatic metabolism accounts for its relatively predictable pharmacokinetics.

Elimination:
Hydroxyurea is predominantly excreted by the kidneys, mainly as unchanged drug. Approximately 40% to 60% of the administered dose is recovered intact in urine within 24 hours. Renal clearance is a major route of elimination, which necessitates caution or dose adjustment in patients with impaired renal function. The plasma half-life averages 3 to 4 hours but can be prolonged if renal clearance is reduced. Minor elimination occurs via feces. The drug’s elimination profile supports once-daily dosing regimens in clinical practice, with close monitoring in populations with compromised kidney function.

Dosage Forms

Available Dosage Forms:
Hydroxyurea is available as oral capsules and tablets in multiple dosage strengths to accommodate various clinical indications and patient needs. Specifically, the formulations include oral capsules of 200 mg, 300 mg, 400 mg, and 500 mg, as well as oral tablets of 100 mg and 1000 mg. These multiple dosage formats enable flexibility in dose titration and optimization based on patient response and tolerability.

Dosages for Adults and Adolescents:
Dosing of hydroxyurea is individualized depending on the treated condition. For chronic myeloid leukemia, initial doses might start at 15 mg/kg orally once daily, with careful titration to achieve hematologic response while minimizing myelosuppression. In sickle cell anemia, doses typically begin at 15 mg/kg/day with escalation to a maximum tolerated dose, commonly not exceeding 35 mg/kg/day, to reduce vaso-occlusive crises and transfusion requirements. For certain cancers such as ovarian or squamous cell carcinomas, dosing regimens are adjusted per oncologist discretion, often incorporating cycles synchronized with other chemotherapeutic agents.

Specific Patient Populations:
In patients with renal impairment, dosage adjustments are necessary due to decreased clearance and increased risk of toxicity; lower starting doses and slower escalation with frequent monitoring of blood counts are prudent. Caution is also advised in hepatic impairment due to potential for exacerbated hematologic effects. Elderly patients may exhibit increased sensitivity to hydroxyurea and require dose modifications accordingly. Pregnant or breastfeeding women should avoid hydroxyurea due to teratogenicity and secretion into breast milk. Pediatric dosing is generally based on weight with close clinical monitoring. Overall, therapy mandates individualized dosing and vigilant hematologic surveillance.

Mechanism Of Action

Hydroxyurea exerts its pharmacological effects primarily through inhibition of the enzyme ribonucleotide reductase (RNR), a critical catalyst in DNA synthesis. By impeding RNR, hydroxyurea depletes the pool of deoxyribonucleotides necessary for DNA replication and repair, effectively arresting cells in the S-phase of the cell cycle. This cytostatic action preferentially affects rapidly dividing cells, such as malignant cells and erythroid precursors, underlying its utility in cancer and hemoglobinopathy treatment.

At the molecular level, hydroxyurea specifically interacts with the tyrosyl free radical at the active site of the small subunit of ribonucleotide reductase. By scavenging this radical, hydroxyurea halts the reduction of ribonucleotides to deoxyribonucleotides, leading to DNA strand synthesis interruption. This results in replication stress, activation of DNA damage response pathways, and eventually cell cycle arrest or apoptosis depending on the cellular context.

In sickle cell disease, hydroxyurea not only reduces cellular proliferation but also induces fetal hemoglobin (HbF) production. The exact mechanism for HbF induction remains incompletely defined but is thought to involve stress erythropoiesis and nitric oxide-related signaling pathways. Elevated HbF reduces the polymerization of sickle hemoglobin, thereby decreasing red blood cell sickling, hemolysis, vaso-occlusion, and associated painful crises. This clinical benefit is a unique aspect of hydroxyurea’s mechanism beyond classic antiproliferative effects.

Comparatively, hydroxyurea's mechanism distinguishes it from cytotoxic chemotherapies that cause DNA crosslinking or strand breaks. Instead, it offers a targeted interruption of nucleotide synthesis, providing a somewhat selective cytostatic effect with a favorable oral bioavailability profile. Clinical studies have demonstrated that this mechanism correlates with improved survival and symptom management in diseases such as chronic myeloid leukemia and sickle cell anemia, affirming its role as a therapeutic mainstay in these conditions.

Pharmacological Actions

Inhibition of ribonucleotide reductase, leading to decreased DNA synthesis and cell cycle arrest in S-phase.
Cytostatic effect preferentially targeting rapidly dividing malignant and hematopoietic cells.
Induction of fetal hemoglobin synthesis in erythroid cells, beneficial in sickle cell anemia management.
Reduction of vaso-occlusive episodes and need for blood transfusions in sickle cell disease.
Antineoplastic activity in chronic myeloid leukemia, ovarian cancer, and certain skin cancers.
Immunosuppressive properties through modulation of proliferating immune cells.
Induction of nitric oxide production contributing to vasodilation and potential clinical effects.
Alteration of cellular redox states influencing apoptosis and DNA repair pathways.
Low plasma protein binding facilitating wide tissue distribution.
Dose-dependent myelosuppression leading to decreased leukocyte and platelet counts.
Modulation of erythropoiesis stress responses, promoting hematologic improvement.
Possible enhancement of radiosensitivity due to interference with DNA repair mechanisms.
Minimal hepatic metabolism reducing potential for cytochrome P450-based drug interactions.
Oral bioavailability allowing convenient once daily dosing.

Therapeutic Or Clinical Uses

Treatment of chronic myeloid leukemia to control leukocytosis and disease progression.
Management of sickle cell anemia to reduce frequency of pain crises and blood transfusions.
Treatment of ovarian cancer, often as part of combination chemotherapy regimens.
Therapy for squamous cell carcinoma of the head and neck to reduce tumor burden.
Adjunctive therapy in polycythemia vera and essential thrombocythemia to control blood counts.
Potential use in other myeloproliferative disorders under specialist guidance.
Reduction of symptoms and complications associated with hemoglobinopathies.
Palliative treatment to improve quality of life in specific hematological malignancies.
Investigational uses in glioblastoma multiforme and other malignancies in clinical trials.
Use in patients unsuitable for intensive chemotherapy due to toxicity profile.
Protection against sickling via increased fetal hemoglobin synthesis in erythrocytes.
Indicator for suppression of leukocyte counts to minimize hyperproliferative complications.
Treatment of resistant or relapsed malignancies following other chemotherapy failure.
Use in combination with radiation for synergistic cancer cell kill in head and neck tumors.
Supportive management for reducing transfusion dependence in chronic anemias.

Side Or Adverse Effects

Myelosuppression manifesting as neutropenia, anemia, and thrombocytopenia.
Gastrointestinal disturbances including nausea, vomiting, diarrhea, and constipation.
Mucositis and painful mouth sores interfering with nutrition and oral intake.
Cutaneous reactions such as skin ulcers, pigmentation changes, and dermatitis.
Peripheral neuropathy presenting as numbness, tingling, or burning pain in extremities.
Increased susceptibility to infections due to immunosuppression.
Bleeding tendencies related to thrombocytopenia and platelet dysfunction.
Fatigue, malaise, and fever as signs of bone marrow suppression or infection.
Hepatotoxicity or pancreatitis evidenced by abdominal pain, jaundice, and elevated enzymes.
Potential teratogenicity causing birth defects and fetal harm if exposed during pregnancy.
Rare development of secondary malignancies including leukemias and skin cancers.
Swelling and discoloration of hands and feet indicative of vascular or soft tissue toxicity.
Alopecia or hair thinning with prolonged therapy.
Hypersensitivity reactions including rash, hives, and respiratory distress.
Drowsiness or central nervous system effects in cases of overdose.

Precautions

Strict use of effective contraception for both men and women during and post treatment.
Regular monitoring of complete blood counts to detect early myelosuppression.
Avoidance of live vaccines during therapy due to increased infection risk.
Careful dose adjustments in patients with renal or hepatic impairment.
Avoidance of skin exposure to sunlight, with use of protective clothing and sunscreen.
Use of disposable gloves when handling medication to prevent dermal absorption and contamination.
Informing healthcare providers of hydroxyurea usage prior to diagnostic laboratory tests.
Close monitoring for signs of infection and prompt treatment thereof.
Avoidance in patients with known hypersensitivity to hydroxyurea or its components.
Consideration of folic acid supplementation as directed by treating physician.
Avoidance of pregnancy during treatment and for extended periods after cessation.
Precautions in elderly due to increased sensitivity to hematologic and systemic effects.
Adjustment or withholding of doses based on hematologic parameters and clinical status.
Education regarding symptoms of toxicity requiring immediate medical attention.
Monitoring for potential drug interactions with concomitant antiviral or chemotherapy agents.

Warnings

Hydroxyurea is teratogenic; both male and female patients must use birth control to prevent pregnancy.
Risk of secondary malignancies including leukemia and skin cancer; patients should use sun protection.
Immunosuppression may predispose to severe infections; avoid live vaccines and contact with sick individuals.
May cause severe myelosuppression necessitating frequent blood count monitoring and dose adjustment.
Do not crush, break, or open capsules or tablets; exposure to powder can cause skin or mucosal irritation.
Potential for liver or pancreatic toxicity; monitor for symptoms such as abdominal pain and jaundice.
Use with caution in patients with existing ulcers or wounds due to impaired healing risk.
Older adults may have increased drug sensitivity necessitating close supervision.
In overdose, severe toxicity including mucositis, drowsiness, and vascular discoloration may occur.
Pregnancy during treatment or shortly afterward carries high risk of birth defects; immediately report pregnancy.
Not to be used in breastfeeding due to potential for neonatal toxicity.
Patients should be advised to avoid sun exposure and use high SPF sunscreen to reduce skin cancer risk.
Drug interactions may increase toxicity; disclose all medications to healthcare providers.
May interfere with laboratory tests; inform all healthcare personnel regarding hydroxyurea therapy.
Discontinue therapy immediately if severe adverse reactions or allergic symptoms develop.

Contraindication

Known hypersensitivity or allergy to hydroxyurea or any component of the formulation.
Pregnancy due to high risk of teratogenicity and fetal harm.
Breastfeeding mothers as hydroxyurea is excreted in breast milk and may harm the infant.
Severe bone marrow suppression or pre-existing pancytopenia.
Active infections where immunosuppression would exacerbate clinical condition.
Severe hepatic or renal impairment without the possibility for close monitoring and dose adjustment.
Open wounds or leg ulcers without appropriate management due to risk of poor healing.
Concurrent use with live attenuated vaccines due to risk of disseminated infection.
Patients with uncontrolled bleeding disorders susceptible to exacerbation by cytopenias.
Known sensitivity to any ingredient in the oral capsule or tablet formulations.
Patients unable to comply with frequent blood monitoring and safety precautions.
Use in children only under specialist guidance with appropriate monitoring.
Contraindicated in patients with previous malignancies dependent on clinical judgement.
History of severe dermatologic reactions to antimetabolites or cytotoxic chemotherapy.
Use cautiously or avoid in patients with significant neurological disorders due to neuropathy risk.

Drug Interactions

Increased risk of myelosuppression when combined with other bone marrow suppressing agents.
Enhanced hematologic toxicity with concomitant antiviral therapies, particularly zidovudine.
Potential interaction with interferons augmenting immunosuppression and cytopenias.
Minimal cytochrome P450 metabolic interactions, but caution advised with other chemotherapeutics.
Avoid live vaccines during hydroxyurea therapy to prevent vaccine-derived infections.
Drugs increasing uric acid levels may exacerbate hydroxyurea-induced hyperuricemia.
Co-administration with other folate antagonists may potentiate hematologic toxicity.
Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase bleeding risk in presence of thrombocytopenia.
Concomitant use with nephrotoxic drugs requires careful renal function monitoring.
Possible interaction with medications altering renal clearance leading to altered hydroxyurea levels.
Drugs affecting bone marrow function, such as methotrexate, may have additive toxicities.
Reduced effectiveness of vaccines due to hydroxyurea-induced immunosuppression.
Potential additive gastrointestinal toxicity with other cytotoxic agents.
Patients should inform healthcare providers of all prescription and over-the-counter medications to avoid adverse interactions.
Use caution with herbal supplements due to unknown effects on hematologic parameters.

Preparations Of The Drug

Oral capsules containing 200 mg, 300 mg, 400 mg, and 500 mg hydroxyurea.
Oral tablets available in 100 mg and 1000 mg strengths.
Packaging designed to minimize accidental exposure and facilitate dosing accuracy.
Standard formulation as immediate-release oral dosage forms for systemic absorption.
Storage requirements include room temperature protection from moisture and heat.
Capsules and tablets supplied with patient information leaflets detailing safe handling.
Single-ingredient preparations without combination with other agents.
Availability may vary by country and manufacturer with branded products such as Droxia, Hydrea, Siklos, Mylocel, and Xromi.
Blister packs and bottles available depending on manufacturer and dispensing practices.
Instructions emphasize not to crush, break, or open capsules or tablets to prevent exposure.
Prescribed in various package sizes to accommodate acute and chronic therapy needs.
Production adheres to regulatory standards to ensure potency and purity.
Supplemental formulations of folic acid are often recommended concomitantly but dispensed separately.
Medicine guides included to aid patient understanding of usage, precautions, and potential side effects.
Healthcare providers should counsel patients on proper storage and disposal to prevent accidental exposure.